You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

258 Results
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Palliative
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    idelalisib - For the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, according to specific clinical criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
Regimen
Cancer Type:
Sarcoma, 
Ewing's
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative, Palliative
Nov 2017
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For the treatment of patients with relapsed or refractory Waldenstrӧm Macroglobulinemia, as monotherapy, based on criteria
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Mar 2021

Pages